Journal of the American Academy of Dermatology
Volume 61, Issue 6 , Pages 1044-1055 , December 2009

Treatment of psoriasis in patients with hepatitis C: From the Medical Board of the National Psoriasis Foundation

  • Amylynne J. Frankel, MD

      Affiliations

    • Department of Dermatology, Tufts Medical Center, Boston, Massachusetts
    • ,
  • Abby S. Van Voorhees, MD

      Affiliations

    • Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania
    • ,
  • Sylvia Hsu, MD

      Affiliations

    • Department of Dermatology, Baylor College of Medicine, Houston, Texas
    • ,
  • Neil J. Korman, MD, PhD

      Affiliations

    • Department of Dermatology and the Murdough Family Center for Psoriasis, Case Western Reserve University/University Hospital of Cleveland, Cleveland, Ohio
    • ,
  • Mark G. Lebwohl, MD

      Affiliations

    • Department of Dermatology, Mount Sinai School of Medicine, New York University, New York, New York
    • ,
  • Bruce F. Bebo Jr., PhD

      Affiliations

    • National Psoriasis Foundation, Portland, Oregon
    • ,
  • Alice B. Gottlieb, MD, PhD

      Affiliations

    • Department of Dermatology, Tufts Medical Center, Boston, Massachusetts
    • Corresponding Author InformationReprint requests: Alice B. Gottlieb, MD, PhD, Department of Dermatology, Tufts Medical Center, 800 Washington St, Tufts-NEMC #114, Boston, MA 02111.
    • ,
  • National Psoriasis Foundation

References 

  1. Magliocco MA, Gottlieb AB. Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection: report of 3 cases. J Am Acad Dermatol. 2004;51:580–584
  2. Calabrese LH, Zein N, Vassilopoulos D. Safety of antitumor necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection. Ann Rheum Dis. 2004;63(Suppl):ii18–24
  3. Zein NN. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J Hepatol. 2005;42:315–322
  4. Citro V, Fristachi R, Tarantino G. Extensive psoriasis induced by pegylated interferon: a case report. J Med Case Rep. 2007;1:86
  5. Taylor C, Burns DA, Wiselka MJ. Extensive psoriasis induced by interferon alfa treatment for chronic hepatitis C. Postgrad Med J. 2000;76:365–367
  6. Methotrexate [package insert]. Bedford, OH: Bedford Laboratories; 2005;
  7. Neoral (cyclosporine) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2002;
  8. Soriatane [package insert]. Nutley, NJ: Roche Laboratories; 1997;
  9. Enbrel (etanercept) [package insert]. Thousand Oaks, CA: Immunex Corp; 2004;
  10. Pariser DM, Wyles RJ. Toxic hepatitis from oral methoxsalen photochemotherapy (PUVA). J Am Acad Dermatol. 1980;3:248–250
  11. Clements PJ, Davis J. Cytotoxic drugs: their clinical application to the rheumatic diseases. Semin Arthritis Rheum. 1986;15:231–254
  12. Markin RS, Donovan JP, Shaw BW, Zetterman RK. Fulminant hepatic failure after methotrexate and PUVA therapy for psoriasis. J Clin Gastroenterol. 1993;17:311–313
  13. Ashton RE, Millward-Sadler GH, White JE. Complications in methotrexate treatment of psoriasis with particular reference to liver fibrosis. J Invest Dermatol. 1982;79:229–232
  14. Orion E, Matz H, Wolf R. The life-threatening complications of dermatologic therapies. Clin Dermatol. 2005;23:182–192
  15. Shekelle PG, Woolf SH, Eccles M, Grimshaw J. Clinical guidelines: developing guidelines. BMJ. 1999;318:593–596
  16. Thaci D, Patzold S, Kaufmann R, Boehncke WH. Treatment of psoriasis with alefacept in patients with hepatitis C infection: a report of two cases. Br J Dermatol. 2005;152:1048–1050
  17. Bellisai F, Giannitti C, Donvito A, Galeazzi M. Combination therapy with cyclosporine A and anti-TNF-alpha agents in the treatment of rheumatoid arthritis and concomitant hepatitis C virus infection. Clin Rheumatol. 2007;26:1127–1129
  18. Imafuku S, Tashiro A, Furue M. Ciclosporin treatment of psoriasis in a patient with chronic hepatitis C. Br J Dermatol. 2007;156:1367–1369
  19. Feldman SR, Gelfand JM, Stein Gold L, Jones SD. The role of topical therapy for patients with extensive psoriasis. Cutis. 2007;79:18–31
  20. Gorgievska Sukarovska B, Lipozencic J. Topical management of psoriasis–corticosteroids and sparing corticosteroid therapy. Acta Dermatovenerol Croat. 2006;14:188–196
  21. Dawe RS, Cameron H, Yule S, Man I, Ibbotson SH, Ferguson J. UV-B phototherapy clears psoriasis through local effects. Arch Dermatol. 2002;138:1071–1076
  22. Simon JC, Pfieger D, Schopf E. Recent advances in phototherapy. Eur J Dermatol. 2000;10:642–645
  23. Jones CD, Guckian M, el-Ghorr AA, Gibbs NK, Norval M. Effects of phototherapy on the production of cytokines by peripheral blood mononuclear cells and on systemic antibody responses in patients with psoriasis. Photodermatol Photoimmunol Photomed. 1996;12:204–210
  24. Nyfors A, Dahl-Nyfors B, Hopwood D. Liver biopsies from patients with psoriasis related to photochemotherapy (PUVA): findings before and after 1 year of therapy in twelve patients; a blind study and review of literature on hepatotoxicity of PUVA. J Am Acad Dermatol. 1986;14:43–48
  25. Zachariae H, Kragballe K, Sogaard H. Liver biopsy in PUVA-treated patients. Acta Derm Venereol. 1979;59:268–270
  26. Bjellerup M, Bruze M, Hansson A, Krook G, Ljunggren B. Liver injury following administration of 8-methoxypsoralen during PUVA therapy. Acta Derm Venereol. 1979;59:371–372
  27. Bjellerup M, Bruze M, Krook G, Ljunggren B. Toxic hepatitis after PUVA. J Am Acad Dermatol. 1981;4:481
  28. Weiss VC, Layden T, Spinowitz A, Buys CM, Nemchausky BA, West DP, et al. Chronic active hepatitis associated with etretinate therapy. Br J Dermatol. 1985;112:591–597
  29. Vahlquist A, Loof L, Nordlinder H, Rollman O, Vahlquist C. Differential hepatotoxicity of two oral retinoids (etretinate and isotretinoin) in a patient with palmoplantar psoriasis. Acta Derm Venereol. 1985;65:359–362
  30. Vahlquist A. Long-term safety of retinoid therapy. J Am Acad Dermatol. 1992;27(Suppl):S29–S33
  31. Katz HI, Waalen J, Leach EE. Acitretin in psoriasis: an overview of adverse effects. J Am Acad Dermatol. 1999;41(Suppl):S7–12
  32. Roenigk HH, Callen JP, Guzzo CA, Katz HI, Lowe N, Madison K, et al. Effects of acitretin on the liver. J Am Acad Dermatol. 1999;41:584–588
  33. Cecchi R, Bartoli L. Psoriasis and hepatitis C treated with anti-TNF alpha therapy (etanercept). Dermatol Online J. 2006;12:4
  34. Rokhsar C, Rabhan N, Cohen SR. Etanercept monotherapy for a patient with psoriasis, psoriatic arthritis, and concomitant hepatitis C infection. J Am Acad Dermatol. 2006;54:361–362
  35. De Simone C, Paradisi A, Capizzi R, Carbone A, Siciliano M, Amerio PL. Etanercept therapy in two patients with psoriasis and concomitant hepatitis C. J Am Acad Dermatol. 2006;54:1102–1104
  36. Marotte H, Fontanges E, Bailly F, Zoulim F, Trepo C, Miossec P. Etanercept treatment for three months is safe in patients with rheumatological manifestations associated with hepatitis C virus. Rheumatology (Oxford). 2007;46:97–99
  37. Niewold TB, Gibofsky A. Concomitant interferon-alpha therapy and tumor necrosis factor alpha inhibition for rheumatoid arthritis and hepatitis C. Arthritis Rheum. 2006;54:2335–2337
  38. Linardaki G, Katsarou O, Ioannidou P, Karafoulidou A, Boki K. Effective etanercept treatment for psoriatic arthritis complicating concomitant human immunodeficiency virus and hepatitis C virus infection. J Rheumatol. 2007;34:1353–1355
  39. Peterson JR, Hsu FC, Simkin PA, Wener MH. Effect of tumor necrosis factor alpha antagonists on serum transaminases and viremia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum Dis. 2003;62:1078–1082
  40. Roux CH, Brocq O, Breuil V, Albert C, Euller-Ziegler L. Safety of anti-TNF-alpha therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis. Rheumatology (Oxford). 2006;45:1294–1297
  41. Oniankitan O, Duvoux C, Challine D, Mallat A, Chevalier X, Pawlotsky JM, et al. Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C. J Rheumatol. 2004;31:107–109
  42. Abdelmalek MF, Liu C, Valentine JF. Successful treatment of chronic hepatitis C with pegylated interferon, ribavirin, and infliximab in a patient with Crohn's disease. Am J Gastroenterol. 2007;102:1333–1334
  43. Aslanidis S, Vassiliadis T, Pyrpasopoulou A, Douloumpakas I, Zamboulis C. Inhibition of TNFalpha does not induce viral reactivation in patients with chronic hepatitis C infection: two cases. Clin Rheumatol. 2007;26:261–264
  44. Khanna M, Shirodkar MA, Gottlieb AB. Etanercept therapy in patients with autoimmunity and hepatitis C. J Dermatolog Treat. 2003;14:229–232
  45. Helliwell PS, Taylor WJ. Treatment of psoriatic arthritis and rheumatoid arthritis with disease modifying drugs–comparison of drugs and adverse reactions. J Rheumatol. 2008;35:472–476
  46. Vigna-Perez M, Abud-Mendoza C, Portillo-Salazar H, Alvarado-Sanchez B, Cuevas-Orta E, Moreno-Valdes R, et al. Immune effects of therapy with adalimumab in patients with rheumatoid arthritis. Clin Exp Immunol. 2005;141:372–380
  47. Everson GT. Impact of immunosuppressive therapy on recurrence of hepatitis C. Liver Transpl. 2002;8:S19–S27
  48. Oton E, Barcena R, Castillo M, Barreales M, Blesa C, Moreno-Planas JM, et al. Hepatitis C virus recurrence after liver transplantation: influence of immunosuppressive regimens on viral load and liver histology. Transplant Proc. 2006;38:2499–2501
  49. Kamar N, Selves J, Sandres-Saune K, Durand D, Izopet J, Rostaing L. Does cyclosporine have a beneficial effect on the course of chronic hepatitis C infection after renal transplantation?. Transplant Proc. 2006;38:1329–1332
  50. Raptiva [package insert] . South. San Francisco, CA: Genentech Inc; 2005;
  51. Stangle JR, Carroll KL, Illichman M, Striker R. Effect of antimetabolite immunosuppressants on flaviviridae, including hepatitis C virus. Transplantation. 2004;77:562–567
  52. Platz KP, Mueller AR, Berg T, Neuhaus R, Hopf U, Lobeck H, et al. Searching for the optimal management of hepatitis C patients after liver transplantation. Transplant Int. 1998;1:S209–S211
  53. Henry SD, Metselaar HJ, Lonsdale RC, Kok A, Haagmans BL, Tilanus HW, et al. Mycophenolic acid inhibits hepatitis C virus replication and acts in synergy with cyclosporin A and interferon-alpha. Gastroenterology. 2006;131:1452–1462
  54. Luan FL, Schaubel DE, Zhang H, Jia X, Pelletier SJ, Port FK, et al. Impact of immunosuppressive regimen on survival of kidney transplant recipients with hepatitis C. Transplantation. 2008;85:1601–1606
  55. Ashcroft DM, Po ALW, Williams HC, Griffiths CEM. Systematic review of comparative efficacy and tolerability of calcipotriol in treating chronic plaque psoriasis. BMJ. 2000;320:963–967
  56. Zonneveld IM, Rubins A, Jablonska S, Dobozy A, Ruzicka T, Kind P, et al. Topical tacrolimus is not effective in chronic plaque psoriasis. A pilot study. Arch Dermatol. 1998;134:1101–1102
  57. Lebwohl M, Freeman AK, Chapman MS, Feldman SR, Hatrle JE, Henning A. Tacrolimus ointment is effective for facial and intertriginous psoriasis. J Am Acad Dermatol. 2004;51:723–730
  58. Gribetz C, Ling M, Lebwohl M, Pariser D, Draelos Z, Gottlieb AB, et al. Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study. J Am Acad Dermatol. 2004;51:731–738
  59. Cameron H, Dawe RS, Yule S, Murphy J, Ibbotson SH, Ferguson J. A randomized, observer-blinded trial of twice vs three times weekly narrowband ultraviolet B phototherapy for chronic plaque psoriasis. Br J Dermatol. 2002;147:973–978
  60. Parrish JA, Fitzpatrick TB, Tanenbaum L, Pathak MA. Photochemotherapy of psoriasis with oral methoxsalen and longwave ultraviolet light. N Engl J Med. 1974;291:1207–1211
  61. Wolff KW, Fitzpatrick TB, Parrish JA, Gschnait F, Gilchrest B, Hönigsmann H, et al. Photochemotherapy for psoriasis with orally administered methoxsalen. Arch Dermatol. 1976;112:943–950
  62. Weismann K, Howitz J, Bro-Joergensen A. Treatment of resistant psoriasis with oral 8-methoxypsoralen and long-wave ultraviolet light (PUVA): A treatment schedule and a follow-up study. Acta Derm Venereol (Stockh). 1977;57:73–76
  63. Melski JW, Tannenbaum L, Parrish JA, Fitzpatrick TB, Bleich HL. Oral methoxsalen photochemotherapy for the treatment of psoriasis: a cooperative clinical trial. J Invest Dermatol. 1977;68:328–335
  64. Martin P, Busuttil RW, Goldstein RM, Crippin JS, Klintmalm GB, Fitzsimmons WE, et al. Impact of tacrolimus versus cyclosporine in hepatitis C virus-infected liver transplant recipients on recurrent hepatitis: a prospective, randomized trial. Liver Transpl. 2004;10:1258–1262
  65. Durak I, Ozbek H, Serenay E. Cyclosporine reduces hepatic antioxidant capacity: protective roles of antioxidants. Int Immunopharmacol. 2004;4:469–473
  66. Henry SD, Metselaar HJ, Lonsdale RC, Kok A, Haagmans BL, Tilanus HW, et al. Mycophenolic acid inhibits hepatitis C virus replication and acts in synergy with cyclosporin A and interferon-alpha. Gastroenterology. 2006;131:1452–1462
  67. Firpi RJ, Nelson DR, Davis GL. Lack of antiviral effect of a short course of mycophenolate mofetil in patients with chronic hepatitis C virus infection. Liver Transpl. 2003;9:57–61
  68. Rostaing L, Izopet J, Sandres K, Cisterne JM, Puel J, Durand D. Changes in hepatitis C virus RNA viremia concentrations in long-term renal transplant patients after introduction of mycophenolate mofetil. Transplantation. 2000;69:991–994

 Funding sources: None.

 Disclosure: Dr Van Voorhees has served as a consultant/speaker/advisor for Amgen, Abbott, Biogen, Centocor, Genentech, Incyte, Warner Chilcott, Connetics, VGX, and Xtrac. She has been an investigator for Amgen, Astellas, Genentech, Warner Chilcott, Roche, Bristol Myers Squibb, and IDEC. She has served on a drug safety monitoring board for Synta. She also is a stockholder and owns stock options in Merck. Dr Hsu has been a consultant for Abbott, Amgen, Biogen Idec, Centocor, and Genentech. She has been a clinical investigator for Amgen and Centocor. Dr Korman has been a consultant, investigator, or speaker for Abbott, Amgen, Astellas, Centocor, and Genentech. Dr Lebwohl has been a consultant for Abbott, Amgen, Astellas, Centocor, Genentech, UCB Pharma, Stiefel, Triax, Pharmaderm, Medicis, Novartis, and Warner Chilcott. He has been a speaker for Abbott, Amgen, Astellas, Centocor, and Genentech. Dr Bebo is employed by the National Psoriasis Foundation. The Foundation receives unrestricted financial support from Abbott, Centocor, Amgen, Wyeth, Genentech, Astellas, Stiefel, Galderma, Warner Chilcott, and Photomedix. Almost all of Dr Gottlieb's consulting and speaking fees are paid to Tufts Medical Center. Dr Gottlieb is a member of the speakers bureau of Amgen Inc and Wyeth Pharmaceuticals; has current consulting/advisory board agreements with Amgen Inc, Centocor Inc, Wyeth Pharmaceuticals, Celgene Corp, Bristol Myers Squibb Co, Beiersdorf Inc, Warner Chilcott, Abbott, Roche, Sankyo, Medarex, Kemia, Celera, TEVA, Actelion, UCB, Novo Nordisk, Almirall, Immune Control, RxClinical, Dermipsor Ltd, Medacorp, DermiPsor, Can-Fite, Incyte, Corgentech, Magen Biosciences, Stieffel, and Puretech; Tufts Medical Center has received research/educational grants from Centocor Inc, Amgen Inc, Wyeth Pharmaceuticals, Immune Control, Celgene Corp, Pharmacare, Incyte, and Abbott. Dr Frankel has no conflicts of interest to declare.

PII: S0190-9622(09)00396-X

doi: 10.1016/j.jaad.2009.03.044

Journal of the American Academy of Dermatology
Volume 61, Issue 6 , Pages 1044-1055 , December 2009

Article Tools

* Image Usage & Resolution